Uveitis, a Rare but Important Complication of adjuvant Zoledronic acid in breast cancer

Adjuvant therapy has become a crucial part in reducing risk of recurrence after surgical intervention. Bisphosphonates such as zoledronic acid have been used as part of adjuvant therapy. Among its many side-effects, zoledronic acid also carries a risk of uveitis. Uveitis remains one of many lesser-known side-effects; prompt recognition is essential to ensure patients receive appropriate and timely care to help prevent permanent vision loss. We report a case of anterior uveitis in a post-menopausal woman who presented with visual symptoms after receiving the first dose of zoledronic acid. This case report serves to educate and increase awareness of the risk of uveitis in patients who are given zoledronic acid. This is the first and only reported case of zoledronic acid, when used in the adjuvant setting for the treatment of breast cancer.